echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Bristol-Myers Squibb's immune combination therapy approved in China

    Bristol-Myers Squibb's immune combination therapy approved in China

    • Last Update: 2021-06-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On June 10, according to the official website of China National Medical Products Administration (NMPA), Bristol-Myers Squibb's (BMS) immune combination therapy received a drug approval number
    In December 2020, the marketing application (JXSS2000056/JXSS2000054) of the combination therapy intended for the treatment of unresectable non-epithelial malignant pleural mesothelioma in adult patients was approved by the Center for Drug Evaluation (CDE) for priority review

    The approval number obtained this time is the same as the registration acceptance number, which means that the immunocombination therapy of nivolumab and ipilimumab for the treatment of pleural mesothelioma has been officially approved in China


    This combination therapy has previously been demonstrated in the CheckMate-743 study that compared with chemotherapy, it can bring significant and long-lasting overall survival benefits to patients with all types of malignant pleural mesothelioma in the first line
    According to public information, this is the first drug therapy approved for mesothelioma in 16 years


    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.